Cargando…

Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer

BACKGROUND: Resistance to cisplatin-based chemotherapy is associated with poor prognosis in testicular germ cell cancer, emphasising the need for new therapeutic approaches. In this respect, the therapeutic concept of anti-angiogenesis is of particular interest. In a previous study, we presented two...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nitzsche, B, Gloesenkamp, C, Schrader, M, Hoffmann, B, Zengerling, F, Balabanov, S, Honecker, F, Höpfner, M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3504942/ https://www.ncbi.nlm.nih.gov/pubmed/23169338 http://dx.doi.org/10.1038/bjc.2012.481

Ejemplares similares

Novel compounds with antiangiogenic and antiproliferative potency for growth control of testicular germ cell tumours
por: Nitzsche, B, et al.
Publicado: (2010)

Association between ERCC1 and XPA expression and polymorphisms and the response to cisplatin in testicular germ cell tumours
por: Mendoza, J, et al.
Publicado: (2013)

Role of MEK/ERK pathway in the MAD2-mediated cisplatin sensitivity in testicular germ cell tumour cells
por: Fung, M K L, et al.
Publicado: (2006)

Efficacy of cytotoxic agents used in the treatment of testicular germ cell tumours under normoxic and hypoxic conditions in vitro
por: Koch, S, et al.
Publicado: (2003)

Systemic inflammatory markers have independent prognostic value in patients with metastatic testicular germ cell tumours undergoing first-line chemotherapy
por: Fankhauser, Christian Daniel, et al.
Publicado: (2018)

Frequent PD-L1 expression in testicular germ cell tumors
por: Fankhauser, C D, et al.
Publicado: (2015)

Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium
por: Blaheta, R A, et al.
Publicado: (2007)

GAMEC – a new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumours
por: Shamash, J, et al.
Publicado: (2007)

Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells
por: Ioannou, N, et al.
Publicado: (2011)

Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs
por: Gelardi, T, et al.
Publicado: (2008)

Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy
por: Tazzari, M, et al.
Publicado: (2014)

Cisplatin alters nitric oxide synthase levels in human ovarian cancer cells: involvement in p53 regulation and cisplatin resistance
por: Leung, E L, et al.
Publicado: (2008)

Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats
por: Uchino, H, et al.
Publicado: (2005)

Transport kinetics of four- and six-coordinate platinum compounds in the multicell layer tumour model
por: Modok, S, et al.
Publicado: (2007)

Cisplatin-induced apoptosis in human malignant testicular germ cell lines depends on MEK/ERK activation
por: Schweyer, S, et al.
Publicado: (2004)

Tumour hypoxia determines the potential of combining mTOR and autophagy inhibitors to treat mammary tumours
por: Seront, E, et al.
Publicado: (2013)

The role of zinc in the anti-tumour and anti-cachectic activity of D-myo-inositol 1,2,6-triphosphate
por: Russell, S T, et al.
Publicado: (2010)

Regulation of apoptosis-inducing factor-mediated, cisplatin-induced apoptosis by Akt
por: Yang, X, et al.
Publicado: (2008)

Preclinical relevance of dosing time for the therapeutic index of gemcitabine–cisplatin
por: Li, X M, et al.
Publicado: (2005)

Loss of CUL4A expression is underlying cisplatin hypersensitivity in colorectal carcinoma cells with acquired trabectedin resistance
por: Englinger, B, et al.
Publicado: (2017)

In vivo and in vitro properties of STX2484: a novel non-steroidal anti-cancer compound active in taxane-resistant breast cancer
por: Stengel, C, et al.
Publicado: (2014)

Anticancer efficacy of cisplatin and trichostatin A or 5-aza-2′-deoxycytidine on ovarian cancer
por: Meng, F, et al.
Publicado: (2013)

Fractionated (131)I anti-CEA radioimmunotherapy: effects on xenograft tumour growth and haematological toxicity in mice
por: Violet, J A, et al.
Publicado: (2008)

The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models
por: Holt, S V, et al.
Publicado: (2012)

Enzastaurin has anti-tumour effects in lung cancers with overexpressed JAK pathway molecules
por: Shimokawa, T, et al.
Publicado: (2012)

PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models
por: Dredge, K, et al.
Publicado: (2011)

Selective cyclooxygenase-2 silencing mediated by engineered E. coli and RNA interference induces anti-tumour effects in human colon cancer cells
por: Strillacci, A, et al.
Publicado: (2010)

Characterisation and radioimmunotherapy of L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin, in colorectal tumour models
por: El-Emir, E, et al.
Publicado: (2007)

Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs
por: Bianco, R, et al.
Publicado: (2008)

A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels
por: Palumbo, A, et al.
Publicado: (2011)

Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model
por: Hermes, M, et al.
Publicado: (2008)

Adenoviruses-mediated transduction of human oesophageal carcinoma cells with the interferon-λ genes produced anti-tumour effects
por: Li, Q, et al.
Publicado: (2011)

Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies
por: Diaz Miqueli, A, et al.
Publicado: (2009)

Angiogenesis in a human neuroblastoma xenograft model: mechanisms and inhibition by tumour-derived interferon-γ
por: Ribatti, D, et al.
Publicado: (2006)

Fluorescence-guided surgical sampling of glioblastoma identifies phenotypically distinct tumour-initiating cell populations in the tumour mass and margin
por: Piccirillo, S G M, et al.
Publicado: (2012)

Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma
por: Hirashima, K, et al.
Publicado: (2012)

Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms
por: Gujar, S A, et al.
Publicado: (2014)

The endogenous anti-angiogenic VEGF isoform, VEGF(165)b inhibits human tumour growth in mice
por: Rennel, E S, et al.
Publicado: (2008)

Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs
por: Iwasa, T, et al.
Publicado: (2010)

Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity
por: den Brok, M H M G M, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_2fcfi3gbbtsqi72vplkk4tcoje